UNSPSC 51434916: Bendroflumethiazide/rauwolfia serpentina

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434916 Bendroflumethiazide/rauwolfia serpentina, a Commodity code, covers prescription and over-the-counter pharmaceutical products supplied to state and local government health agencies, emergency services, and benefit programs. State and local governments procure under this code to stock medications for emergency medical response, public health programs, and employee/retiree pharmacy benefits. Issuing bodies include city fire and rescue departments, state health and human services agencies, and multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions. Solicitations under the code range from competitive sealed bids for specific medication line items to exploratory requests for information about direct-to-manufacturer contracting models and cooperative purchasing arrangements for multi-source generic pharmaceuticals and OTC products.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa Purchasing Department issued an IFB (Solicitation No. 26P00188, due April 8, 2026) for Advanced Life Support Medications including Labetalol, Epinephrine, Adenosine, and Diltiazem vials for Tampa Fire Rescue, with an estimated contract value of $40,000 and a one-year term plus renewal options; the solicitation included a 5 percent bid discount for Small Local Business Enterprise participation and required Safety Data Sheets compliant with OSHA standards. The Texas Health and Human Services Commission issued an RFI (No. HHS0017013, due April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program aimed at establishing direct relationships between the state's pharmacy benefit program and pharmaceutical manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued an RFP (No. S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with products required to be available in the marketplace by May 15, 2026 and contract terms effective July 1, 2026; evaluation weighted price competitiveness at 75 percent and required vendors to maintain relationships with at least two of three authorized wholesalers and comply with current Good Manufacturing Practices and the Drug Supply Chain Security Act.